-
-
-
-
-
-
-
NewAmsterdam Pharma (NAMS) Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals, Presented
-
-
-
-
-
-
-
Imunon (IMNN) Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy
-
-
-
-
-
-
-
IDEAYA Biosciences (IDYA) Announces FDA IND-Clearance for IDE849
-
-
-
-
-
-
-
TuHURA Biosciences (HURA) Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda in First Line Treatment for MCCUP
-
-
-
-
-
-
-
ImmunityBio (IBRX) receives Refusal to File letter from FDA for sBLA for use of ANKTIVA plus Bacillus Calmette-Guerin
-
-
-
-
-
-
-
Cytokinetics (CYTK) Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy
-
-
-
-
-
-
-
Edwards Lifesciences (EW) TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
-
70,491 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.